 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...

IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...

IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

IN8bio (NASDAQ:INAB  Get Free Report) and Ginkgo Bioworks (NYSE:DNA  Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies...

Contrasting IN8bio (NASDAQ:INAB) and Ginkgo Bioworks (NYSE:DNA)

Ginkgo Bioworks (NYSE:DNA Get Free Report) and IN8bio (NASDAQ:INAB Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk...

IN8bio (NASDAQ:INAB) and Ginkgo Bioworks (NYSE:DNA) Critical Comparison

IN8bio (NASDAQ:INAB  Get Free Report) and Candel Therapeutics (NASDAQ:CADL  Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the...

Comparing IN8bio (NASDAQ:INAB) & Candel Therapeutics (NASDAQ:CADL)

IN8bio, Inc. (NASDAQ:INAB Free Report) Research analysts at HC Wainwright dropped their FY2027 EPS estimates for IN8bio in a report issued on Friday, August 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $1.61 per share for the year, down from their ...

Equities Analysts Issue Forecasts for IN8bio, Inc.'s FY2027 Earnings (NASDAQ:INAB)

NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...

IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

IN8bio, Inc. (NASDAQ:INAB  Free Report)  Investment analysts at HC Wainwright decreased their FY2027 EPS estimates for IN8bio in a research note issued to investors on Friday, August 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $1.61 per share for ...

HC Wainwright Analysts Decrease Earnings Estimates for IN8bio, Inc. (NASDAQ:INAB)

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on IN8bio (INAB Research Report) yesterday and set a price target of $12.00. The... Mizuho Securities analyst Mara Goldstein maintained a Buy rating on IN8bio (INAB  Research Repo...

Mizuho Securities Sticks to Their Buy Rating for IN8bio (INAB)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on IN8bio (INAB Research Report), with a price ta... In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on IN8bio (INAB &#8211...

IN8bio (INAB) Gets a Buy from H.C. Wainwright

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Watchers	892
52-Wk Low	$0.9011
52-Wk High	$3.95

Market Cap	$38.87M
Volume (M)	138,608.00
52-Wk High	$3.95
52-Wk Low	$0.9011

INAB IN8bio Inc

About

Feed

News

Earnings

Fundamentals